Johnson & Johnson and two other major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023.

J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges

June 12, 2025 Shannon Young, Associate Editor/Senior Writer Views

Three major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023 following recalculations [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

J&J, Lilly and GSK to Refund 340B Covered Entities for Overcharges

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Staff Email

Site Footer Live